Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

17.66 +0.46 (+2.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Executive Leadership Change
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Long Term Investor Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 08/25/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of ACADIA Pharmaceuticals Inc. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Looking into ACADIA Pharmaceuticals's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, ACADIA Pharmaceuticals's (NASDAQ:ACAD) reported sales totaled $115.22 million. Despite a 34.54% in earnings, the... 
Via Benzinga
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail. 
Via The Motley Fool
Acadia Pharmaceuticals Inc (ACAD) Q2 2021 Earnings Call Transcript
ACAD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the biggest company by market cap to set a new 52-week low.... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million.... 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
Via Benzinga
10 Stocks Moving In Wednesday's After-Hours Session
Gainers MercadoLibre (NASDAQ: MELI) shares are trading higher after the company reported Q2 EPS of $1.37, up from $1.11 year over year and better-than-expected Q2 sales results.... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Scopus BioPharma (NASDAQ:SCPS) s... 
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
9 Monster Stock Market And Earnings Predictions – Sunday, August 1
Stocks finished the week of July 30 lower, dropping by 40 bps and while the S&P 500 didn’t finish down all that much, we could wonder if last week served as a turning point for the market overall. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
From Acadia Pharmaceuticals Inc.
Via Business Wire
Understanding ACADIA Pharmaceuticals's Unusual Options Activity
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $23.25. Sentiment:... 
Via Benzinga
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
From Acadia Pharmaceuticals Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alterity Therapeutics (NASDAQ:ATHE 
Via Benzinga
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.